MX2020009999A - Composiciones farmacéuticas para inhibir citocinas inflamatorias. - Google Patents

Composiciones farmacéuticas para inhibir citocinas inflamatorias.

Info

Publication number
MX2020009999A
MX2020009999A MX2020009999A MX2020009999A MX2020009999A MX 2020009999 A MX2020009999 A MX 2020009999A MX 2020009999 A MX2020009999 A MX 2020009999A MX 2020009999 A MX2020009999 A MX 2020009999A MX 2020009999 A MX2020009999 A MX 2020009999A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
inflammatory cytokines
inhibiting inflammatory
inhibiting
cytokines
Prior art date
Application number
MX2020009999A
Other languages
English (en)
Inventor
Naftali Primor
Original Assignee
S I S Shulov Innovative Science Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S I S Shulov Innovative Science Ltd filed Critical S I S Shulov Innovative Science Ltd
Publication of MX2020009999A publication Critical patent/MX2020009999A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones farmaceuticas que comprenden tetrapeptidos específicos, para su uso para reducir la liberacion o inhibir la actividad de citocinas y mediadores inflamatorios y en el tratamiento de enfermedades y trastornos asociados con estas citocinas y mediadores.
MX2020009999A 2018-03-29 2019-03-28 Composiciones farmacéuticas para inhibir citocinas inflamatorias. MX2020009999A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862649940P 2018-03-29 2018-03-29
PCT/IL2019/050359 WO2019186561A1 (en) 2018-03-29 2019-03-28 Pharmaceutical compositions for inhibiting inflammatory cytokines

Publications (1)

Publication Number Publication Date
MX2020009999A true MX2020009999A (es) 2020-11-06

Family

ID=68058011

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009999A MX2020009999A (es) 2018-03-29 2019-03-28 Composiciones farmacéuticas para inhibir citocinas inflamatorias.

Country Status (15)

Country Link
US (2) US11419913B2 (es)
EP (1) EP3773661A4 (es)
JP (2) JP7421219B2 (es)
KR (1) KR20200138326A (es)
CN (1) CN112203674A (es)
AU (1) AU2019245521A1 (es)
BR (1) BR112020019347A2 (es)
CA (1) CA3094295A1 (es)
IL (1) IL277436A (es)
MX (1) MX2020009999A (es)
PH (1) PH12020551573A1 (es)
SG (1) SG11202009257TA (es)
UA (1) UA126941C2 (es)
WO (1) WO2019186561A1 (es)
ZA (1) ZA202006412B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220401336A1 (en) * 2019-09-26 2022-12-22 S.I.S. Shulov Innovative Science Ltd. Anti-aging compositions and methods of use thereof
WO2021059267A1 (en) * 2019-09-26 2021-04-01 S.I.S. Shulov Innovative Science Ltd. Compositions and methods for treating degenerative, age-related and trauma-induced disorders
US20230128280A1 (en) 2020-10-23 2023-04-27 Lg Energy Solution, Ltd. Electrode Insulation Liquid Supply Apparatus and Electrode Insulation Liquid Supply Method
WO2022254429A1 (en) * 2021-05-31 2022-12-08 S.I.S. Shulov Innovative Science Ltd. Compositions and methods for treating respiratory distress

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1195762B (it) * 1980-10-13 1988-10-27 Reiner Alberto Real Sas Derivati idrosolubili della cefalexina e procedimento per la loro produzione
IT1172391B (it) 1983-12-23 1987-06-18 Polifarma Spa Composti tirpeptidici contenenti acido piroglutaminico e triptofano,procedimentio di produzione ed applicazioni terapeutiche
US6090790A (en) 1989-12-14 2000-07-18 Eriksson; Elof Gene delivery by microneedle injection
AR026801A1 (es) 2000-01-12 2003-02-26 Medidom Lab Sustancias para uso en el tratamiento de la psoriasis
IL137820A (en) * 2000-08-10 2009-06-15 S I S Shulov Inst For Science Pharmaceutical composition for topical administration comprising an analgesic peptide
EP2268279A1 (en) 2008-03-24 2011-01-05 Celgene Corporation Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl¨-3-oxoisoindoline-4-yl}carboxamide
WO2010032322A1 (ja) 2008-09-22 2010-03-25 日清ファルマ株式会社 抗炎症性ペプチド
KR101290745B1 (ko) * 2010-06-03 2013-07-29 한국해양과학기술원 라말린을 함유하는 염증질환 또는 면역질환의 예방 또는 치료용 약학 조성물
EP2691103B1 (en) * 2011-03-28 2016-07-20 S.I.S. Shulov Innovative Science Ltd. Method for treating disorders of the skin
WO2015197193A2 (en) * 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
CN103724204B (zh) 2013-11-27 2016-05-11 北京化工大学 一种水溶性引发剂及制备
KR20170021349A (ko) * 2014-06-26 2017-02-27 자이겐 인플라메이션 리미티드 다양한 질병의 치료를 위한 jnk 신호 전달 경로의 세포 투과성 펩타이드 억제자의 새로운 용도

Also Published As

Publication number Publication date
CN112203674A (zh) 2021-01-08
BR112020019347A2 (pt) 2021-02-17
JP2021519773A (ja) 2021-08-12
SG11202009257TA (en) 2020-10-29
JP2024015099A (ja) 2024-02-01
US11419913B2 (en) 2022-08-23
RU2020134114A (ru) 2022-04-29
EP3773661A1 (en) 2021-02-17
WO2019186561A1 (en) 2019-10-03
AU2019245521A1 (en) 2020-11-12
CA3094295A1 (en) 2019-10-03
UA126941C2 (uk) 2023-02-22
US20210138023A1 (en) 2021-05-13
ZA202006412B (en) 2023-03-29
EP3773661A4 (en) 2021-12-08
PH12020551573A1 (en) 2021-09-13
JP7421219B2 (ja) 2024-01-24
US20220387547A1 (en) 2022-12-08
KR20200138326A (ko) 2020-12-09
IL277436A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
PH12017501611A1 (en) Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
MX2020012602A (es) Composiciones bacterianas dise?adas y usos de las mismas.
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
MX2022007994A (es) Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos.
EP3583113A4 (en) USE OF TGF-ALPHA FOR TREATMENT OF DISEASES AND DISORDERS
PH12017501980A1 (en) The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
WO2020109233A3 (en) Trmt2a inhibitors for use in the treatment of polyglutamine diseases
MX2021007486A (es) Hidrolizado de colageno para usarse con trastornos de la piel y trastornos intestinales.